Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Kohl's Corporation (KSS) Price & Performance

ADMA Biologics Inc
Kohl's Corporation

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs Kohl's Corporation — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Kohl's Corporation trades at $16 (market cap $1.90B). The key difference: ADMA Biologics Inc and Kohl's Corporation are close in size by market cap, and Kohl's Corporation pays a 2.98% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAKSS
Market Cap
$2.13B$1.90B
Sector
HealthConsumer Cyclical
52-Week High
$20.38$24.71
52-Week Low
$7.60$9.08
Enterprise Value
$2.20B$8.00B
Dividend Yield
2.98%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Kohl's Corporation

Kohl's (KSS) trades at $16.76, down 7.86% on the day, with the stock showing mixed technical signals amid a broader turnaround effort. The company demonstrates improving fundamentals with recent earnings beats and proprietary brand growth, though revenue continues to decline. Valuation metrics appear attractive with a P/E of 7.1 and P/S of 0.12, while technical indicators show bullish moving averages but neutral oscillators.

Kohl's presents a compelling value opportunity with strong proprietary brand momentum and cost controls, though execution risks remain high amid declining sales and intense retail competition. The stock's current price aligns with analyst consensus targets, suggesting limited near-term upside without clearer evidence of sustainable revenue growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Kohl's Corporation

Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

Read more on KSS